Advancesin bioinformatics and genomic data analysis have enabled the identification ofcancer antigens that are generally overlooked during immune surveillance; theseneoantigens have been shown to possess substantial therapeutic potential
RootsAnalysis is pleased to announce the publication of its recent study, titled, “Neoantigen Targeted Therapies Market, 2021-2030.”
Thereport features an extensive study of the current market landscape, offering aninformed opinion on the likely adoption of these therapeutics over the nextdecade. It features an in-depth analysis, highlighting the capabilities ofvarious stakeholders engaged in this domain. In addition to other elements, thestudy includes:
· A detailed assessment of the current marketlandscape of developers engaged in the development of neoantigen targetedtherapies.
· Detailed profiles of developers of neoantigentargeted therapies (shortlisted on the basis of the number of pipelineproducts).
· A detailed publication analysis of close to300 peer-reviewed, scientific articles published during the period 2015-2019(till February), highlighting the research focus within the industry.
· An in-depth analysis of the various patentsthat have been filed / granted related to neoantigens.
· An analysis of the various partnerships pertainingto neoantigen targeting therapies.
· An analysis of the investments made atvarious stages of development in companies that are focused on developingneoantigen targeted therapies.
GetDetailed Analysis: https://www.rootsanalysis.com/reports/view_document/neoantigen-targeted-therapies-market-2019-2030/257.html
Adetailed market forecast, featuring analysis of the current and projectedfuture opportunity across key market segments (listed below)
TargetDisease Indication
· Bone and Cartilage Cancer
· Colorectal Cancer
· Head and Neck Cancer
· Renal Carcinoma
· Hepatocellular Carcinoma
· Lung Cancer
· Gynecological Cancer
· Others
Typeof Treatment
· Personalized
· Off-the-shelf
Typeof Immunotherapy
· Dendritic Cell Vaccine
· DNA / RNA-based Vaccine
· Protein / Peptide-based Vaccine
· TIL-based Therapy
Routeof Administration
· Intradermal
· Intravenous
· Subcutaneous
· Others
KeyGeographical Region
· North America (US)
· Europe (UK, Germany, France, Italy, and Spain
· Rest of the World
Transcriptsof interviews held with the following senior level representatives ofstakeholder companies:
· Gabriel Nistor, Chief Scientific Officer,AIVITA Biomedical
· Ella Sorani, Vice President Research andDevelopment, BioLineRx
· Heinz Lubenau, Chief Operating Officer andCo-Founder, VAXIMM
Keycompanies covered in the report
· Bavarian Nordic
· Genocea Biosciences
· Gradalis
· Immunicum
· Immunovative Therapies
· Iovance Biotherapeutics
· Medigene
· Neon Therapeutics
· Precision Biologics
· Vaxon Biotech
Getan Exclusive PDF Sample
https://www.rootsanalysis.com/reports/257/request-sample.html
ChapterOutlines
Chapter1provides an executive summary of the insights captured in our research. Itoffers a high-level view on the state of the market for neoantigen targetedtherapies, in the short-mid term and long term.
Chapter2provides a general overview of neoantigen targeted therapies, featuring briefdescriptions of the various conventional forms of therapy that are used for thetreatment of oncological disorders. It also includes a discussion on the adventand evolution of cancer immunotherapy, while highlighting its limitations. Thechapter lays emphasis on the role of neoantigens in cancer immunotherapy,providing details on the various types of neoantigens, productdevelopment-related aspects of neoantigen targeted therapies and the diversestrategies that are available / being investigated for delivery ofneoantigen-based therapeutics.
Chapter3includes information on nearly 150 molecules that are currently underdevelopment for the treatment of various cancer indications. It features acomprehensive analysis of pipeline molecules, highlighting phase of development(marketed, clinical and preclinical / discovery stage) of lead candidates, typeof molecule (small molecule and biologic), type of treatment (personalized andoff-the-shelf), type of therapy (monotherapy and combination therapy), type ofimmunotherapy, target indication, line of treatment, and route ofadministration of the drugs / therapies that are being developed for thetreatment of cancer. In addition, the chapter provides information on drugdeveloper(s), highlighting year of their establishment, location ofheadquarters and employee strength.
Chapter4provides detailed profiles of some of the leading stakeholders in this field(shortlisted on the basis of number of pipeline products). Each profilepresents a brief overview of the company, its financial information (if available),product portfolio, recent collaborations and an informed future outlook.
Chapter5provides detailed profiles of some of the leading stakeholders in this field(shortlisted on the basis of number of pipeline products). Each profilepresents a brief overview of the company, its financial information (ifavailable), product portfolio, recent collaborations and an informed futureoutlook.
Chapter6provides a detailed analysis of close to 300 research articles related toneoantigen targeted therapies, published in the period 2015-2019 (tillFebruary). The analysis takes into consideration several aspects, namely targetdisease indications, affiliated cancer immunotherapies, and analysis based onvarious relevant parameters, such as study type (review article, researcharticle and meta-analysis), year of publication, and most popular journals (interms of number of articles published in the given time period), within thisdomain.
AboutRoots Analysis
RootsAnalysis is one of the fastest growing marketresearch companies, sharing fresh and independent perspectives in thebio-pharmaceutical industry. The in-depth research, analysis and insights aredriven by an experienced leadership team which has gained many years ofsignificant experience in this sector. If you’d like help with your growingbusiness needs, get in touch at info@rootsanalysis.com
ContactInformation
RootsAnalysis Private Limited
GauravChaudhary
+1(415) 800 3415
Gaurav.Chaudhary@rootsanalysis.com
Alsohave a Look on Our Upcoming Research Reports
Soft Tissue Sarcoma: Pipeline Review,Developer Landscape and Competitive Insights, 2021-2031
Spinal Muscular Atrophy Market, 2021-2031
